Zenas BioPharma (NASDAQ:ZBIO) Director Hongbo Lu Acquires 25,985 Shares

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Hongbo Lu bought 25,985 shares of the stock in a transaction on Wednesday, February 11th. The stock was purchased at an average price of $22.50 per share, for a total transaction of $584,662.50. Following the completion of the purchase, the director owned 347,968 shares of the company’s stock, valued at approximately $7,829,280. This trade represents a 8.07% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Zenas BioPharma Stock Up 1.1%

ZBIO stock opened at $26.40 on Friday. The stock has a fifty day moving average of $27.56 and a 200-day moving average of $25.58. Zenas BioPharma, Inc. has a fifty-two week low of $6.11 and a fifty-two week high of $44.60. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.73 and a beta of -1.50. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Hedge Funds Weigh In On Zenas BioPharma

A number of large investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in Zenas BioPharma during the fourth quarter valued at about $38,000. Quarry LP boosted its stake in shares of Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the period. Russell Investments Group Ltd. bought a new position in shares of Zenas BioPharma in the third quarter worth approximately $30,000. CWM LLC increased its stake in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after buying an additional 709 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Zenas BioPharma in the fourth quarter worth $95,000.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ZBIO. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Wedbush reiterated an “outperform” rating and issued a $45.00 target price on shares of Zenas BioPharma in a research note on Monday, December 22nd. HC Wainwright restated a “buy” rating and set a $44.00 price target on shares of Zenas BioPharma in a research report on Tuesday. Wall Street Zen cut Zenas BioPharma from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Finally, Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.